Overview Dividends

(ELV) Elevance Health - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0367521038

Health Plans, Pharmacy Services, Specialty Insurance, Care Management

Managed Health Care
Market Cap in USD: 76,716m

IPO / Inception: 2001-01-02
Return 12m vs S&P 500: -19.4%

EPS (Earnings per Share)

EPS CAGR: 4.35%
EPS Trend: 8.3%

Last SUE: 1.95
Qual. Beats: 1

Revenue

Rev. CAGR: 10.49%
Rev. Trend: 95.8%

Last SUE: 1.33
Qual. Beats: 5

Dividends

Dividend Yield	1.99%
Yield on Cost 5y	2.34%
Yield CAGR 5y	14.45%
Payout Consistency	100.0%
Payout Ratio	22.3%

Risk via 5d forecast
Volatility	26.0%
Value at Risk 5%th	39.7%
Relative Tail Risk	-7.35%

Reward TTM
Sharpe Ratio	-0.09
Alpha	-10.99
CAGR/Max DD	-0.22

Character TTM
Hurst Exponent	0.441
Beta	0.173
Beta Downside	0.105

Drawdowns 3y
Max DD	50.38%
Mean DD	17.24%
Median DD	11.02%

Description: ELV Elevance Health December 03, 2025

Elevance Health Inc. (NYSE: ELV) operates as a diversified health-benefits company in the United States, organized into four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The firm delivers a broad portfolio that includes commercial, Medicare, Medicaid and Federal Employee Program (FEP) health plans under the Anthem Blue Cross & Blue Shield, Wellpoint and Carelon brands, as well as supplemental products such as dental, vision, stop-loss and specialty insurance.

Beyond traditional insurance, Elevance runs a sizable pharmacy-services business (CarelonRx) that offers home delivery, specialty pharmacy, formulary management, rebate administration and infusion services. Its Carelon Services arm provides integrated care-management capabilities-behavioral health, utilization management, virtual care, payment integrity, and data-analytics platforms (HealthOS)-to support both internal plans and external payers.

Key performance indicators from the most recent fiscal year (2023) show total revenue of roughly $145 billion, enrollment of about 57 million members, and a medical loss ratio (MLR) hovering near 84 %, reflecting the industry-wide pressure from rising drug costs and inflationary health-care spending. Primary sector drivers include the aging U.S. population (projected Medicare enrollment growth of ~4 % per year through 2030) and regulatory trends such as the ongoing implementation of the Inflation Reduction Act, which caps drug price increases for Medicare beneficiaries.

For a deeper quantitative breakdown, the ValueRay platform provides granular metrics and scenario analysis to help assess Elevance’s valuation under different market assumptions.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (5.53b TTM) > 0 and > 6% of Revenue (6% = 11.69b TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA 2.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 11.75% (prev 7.58%; Δ 4.18pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.04 (>3.0%) and CFO 4.91b <= Net Income 5.53b (YES >=105%, WARN >=100%)

Net Debt (23.39b) to EBITDA (10.02b) ratio: 2.34 <= 3.0 (WARN <= 3.5)

Current Ratio 1.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (225.8m) change vs 12m ago -3.13% (target <= -2.0% for YES)

Gross Margin 50.46% (prev 27.94%; Δ 22.52pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 162.8% (prev 149.3%; Δ 13.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 6.16 (EBITDA TTM 10.02b / Interest Expense TTM 1.38b) >= 6 (WARN >= 3)

Altman Z'' 3.11

(A) 0.19 = (Total Current Assets 63.78b - Total Current Liabilities 40.88b) / Total Assets 122.75b

(B) 0.29 = Retained Earnings (Balance) 35.59b / Total Assets 122.75b

(D) 0.45 = Book Value of Equity 35.05b / Total Liabilities 78.67b

Total Rating: 3.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 70.56

1. Piotroski 7.0pt

2. FCF Yield 3.76%

3. FCF Margin 1.93%

4. Debt/Equity 0.73

5. Debt/Ebitda 2.34

6. ROIC - WACC (= 4.74)%

7. RoE 12.91%

8. Rev. Trend 95.77%

9. EPS Trend 8.29%

What is the price of ELV shares?

As of December 26, 2025, the stock is trading at USD 343.30 with a total of 458,299 shares traded.
Over the past week, the price has changed by -0.38%, over one month by +2.62%, over three months by +8.96% and over the past year by -6.35%.

Is ELV a buy, sell or hold?

Elevance Health has received a consensus analysts rating of 4.41. Therefore, it is recommended to buy ELV.

Strong Buy: 13
Buy: 5
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ELV price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	389.2	13.4%
Analysts Target Price	389.2	13.4%
ValueRay Target Price	346.1	0.8%

ELV Fundamental Data Overview December 22, 2025

Market Cap USD = 76.72b (76.72b USD * 1.0 USD.USD)
P/E Trailing = 13.8887
P/E Forward = 12.0627
P/S = 0.3938
P/B = 1.7226
P/EG = 0.9885
Beta = 0.525
Revenue TTM = 194.82b USD
EBIT TTM = 8.48b USD
EBITDA TTM = 10.02b USD
Long Term Debt = 31.17b USD (from longTermDebt, last quarter)
Short Term Debt = 929.0m USD (from shortTermDebt, last quarter)
Debt = 32.10b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.39b USD (from netDebt column, last quarter)
Enterprise Value = 100.10b USD (76.72b + Debt 32.10b - CCE 8.71b)
Interest Coverage Ratio = 6.16 (Ebit TTM 8.48b / Interest Expense TTM 1.38b)
FCF Yield = 3.76% (FCF TTM 3.77b / Enterprise Value 100.10b)
FCF Margin = 1.93% (FCF TTM 3.77b / Revenue TTM 194.82b)
Net Margin = 2.84% (Net Income TTM 5.53b / Revenue TTM 194.82b)
Gross Margin = 50.46% ((Revenue TTM 194.82b - Cost of Revenue TTM 96.51b) / Revenue TTM)
Gross Margin QoQ = 14.18% (prev 15.62%)
Tobins Q-Ratio = 0.82 (Enterprise Value 100.10b / Total Assets 122.75b)
Interest Expense / Debt = 1.09% (Interest Expense 351.0m / Debt 32.10b)
Taxrate = 15.58% (219.0m / 1.41b)
NOPAT = 7.16b (EBIT 8.48b * (1 - 15.58%))
Current Ratio = 1.56 (Total Current Assets 63.78b / Total Current Liabilities 40.88b)
Debt / Equity = 0.73 (Debt 32.10b / totalStockholderEquity, last quarter 43.95b)
Debt / EBITDA = 2.34 (Net Debt 23.39b / EBITDA 10.02b)
Debt / FCF = 6.21 (Net Debt 23.39b / FCF TTM 3.77b)
Total Stockholder Equity = 42.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.51% (Net Income 5.53b / Total Assets 122.75b)
RoE = 12.91% (Net Income TTM 5.53b / Total Stockholder Equity 42.87b)
RoCE = 11.45% (EBIT 8.48b / Capital Employed (Equity 42.87b + L.T.Debt 31.17b))
RoIC = 9.70% (NOPAT 7.16b / Invested Capital 73.75b)
WACC = 4.96% (E(76.72b)/V(108.82b) * Re(6.65%) + D(32.10b)/V(108.82b) * Rd(1.09%) * (1-Tc(0.16)))
Discount Rate = 6.65% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -2.14%
[DCF Debug] Terminal Value 77.92% ; FCFE base≈2.61b ; Y1≈2.54b ; Y5≈2.57b
Fair Price DCF = 205.3 (DCF Value 45.63b / Shares Outstanding 222.2m; 5y FCF grow -3.53% → 3.0% )
EPS Correlation: 8.29 | EPS CAGR: 4.35% | SUE: 1.95 | # QB: 1
Revenue Correlation: 95.77 | Revenue CAGR: 10.49% | SUE: 1.33 | # QB: 5
EPS next Quarter (2026-03-31): EPS=10.43 | Chg30d=-0.425 | Revisions Net=-1 | Analysts=16
EPS next Year (2026-12-31): EPS=26.95 | Chg30d=-0.440 | Revisions Net=-4 | Growth EPS=-10.1% | Growth Revenue=+3.2%

Additional Sources for ELV Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle